Meeting
2022 ASCO Annual Meeting
A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.
Authors
Bo Yang
Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
Bo Yang , Qi Xiong , Qi Song , Yaping Long , Gang Guo , Hongzhao Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
ChiCTR1900028022
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4567)
DOI
10.1200/JCO.2022.40.16_suppl.4567
Abstract #
4567
Poster Bd #
58
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.
First Author: Gong-Rang Chen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress.
First Author: Wei Wang
Poster
2024 ASCO Genitourinary Cancers Symposium
A meta-analysis assessing objective response rates with first-line systemic treatment options in locally advanced/metastatic urothelial carcinoma.
First Author: Akshat Saxena
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
First Author: Ke-Feng Ding